Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUCMSC-sEV for Androgenetic Alopecia in Young Men
NCT07203599Phase 2Recruiting
- Sponsor
- Shenzhen People's Hospital
- Start
- Sep 2025
- Primary completion
- Oct 2026
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of hucMSC-sEVs in androgenetic alopecia (AGA) (5 arms), sponsored by Shenzhen People's Hospital. Primary endpoints: Hair density at 24 weeks, Hair diameter at 24 weeks and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
hucMSC-sEVs
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT07203599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07203599.